Led by NDM\u2019s Professor James East, researchers and clinicians have developed major new guidelines for monitoring patients with inflammatory bowel disease (IBD) to prevent them going on to develop bowel cancer.
May is Skin Cancer Awareness Month, and a new study with input from researchers in NDM\u2019s units has revealed that a common virus may positively influence how skin cancer patients respond to current treatments.
A major study in The Lancet Infectious Diseases confirms that single low-dose primaquine is safe and effective in reducing malaria transmission in young children. Analysing data from over 6,000 patients, researchers found it effective even in young children and areas with high malaria burden.
Years of groundwork have led Assistant Professor Dr Thitinan Kitisin to his first major step: leading an advanced vaccine research project in Thailand. With support from MODRA, he\u2019s now developing one of the first tonsil organoid models in the country, a small but important step toward improving how vaccines are tested. Along the way, he\u2019s also passing on practical research skills to the next generation of Thai scientists.
NDM's MSc in International Health and Tropical Medicine (IHTM) celebrated its tenth anniversary as an internationally renowned programme for future global health leaders, with over 100 alumni travelling from around the world to join colleagues, current students and guests in Oxford.
A new study, co-lead by Dr Felipe Galvez-Cancino from the Centre for Immuno-Oncology, has shown that Treg cell depletion can suppress tumour growth in one of the deadliest types of cancer.
Professor Buddha Basnyat has received the NHRC Lifetime Achievement Award for Health Research in Nepal. The Nepal Health Research Council (NHRC) recently conferred its prestigious Lifetime Achievement Award for Health Research upon Professor Basnyat at the 11th National Summit of Health and Population Scientists. This honour recognises his exceptional contributions to medical research and public health over a career spanning more than five decades.
Researchers in the Shi group at Ludwig Cancer Research Oxford have developed a new combination therapy for acute myeloid leukaemia, showing therapeutic promise by promoting differentiation of immature blood cells.
At OUCRU Nepal, microbiologist Sulochana Manandhar spent much of her early career at the lab bench, examining bacteria, fine-tuning methods, and chasing answers to scientific questions. Now, with support from the MODRA programme, she\u2019s leading her first hospital-based study, bringing new attention to neonatal health risks in Nepal.
An international consortium of respiratory scientists, including researchers from NDM\u2019s Experimental Medicine Division, have shed light on the role of inflammation in asthma. Through their findings, they have provided a new way of predicting and preventing asthma attacks.
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to \u00a316.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
Dr Duong Thi Hue Kien, a Post-doc Scientist at OUCRU, has shared her experience of finishing her PhD and kickstarting her career in science. She documents the highs and the lows, as well as how she was able to move forward in her career with support from the MORU\u2013OUCRU Discovery Research Academy.
The Kenya Medical Research Institute (KEMRI) has officially entered into a seven-year Memorandum of Understanding (MoU) with Wellcome, a UK-based charitable foundation, and the University of Oxford. The \u00a391 million agreement was signed at the Wellcome headquarters in London, marking a significant boost for medical research and training in Kenya.
Professor Susanna Dunachie and Dr Caesar Atuire of the Centre for Tropical Medicine and Global Health have been appointed as Co-Associate Directors of the Oxford Global Health initiative.
Cancer Research UK and partners have committed \u00a35.5 million in funding to form a world-leading research team, co-led by NDM\u2019s Professor Simon Leedham. The team\u2019s goal is to make personalised medicine a reality for people with bowel cancer.
The Jenner Institute, in partnership with the Coler Lab at Seattle Children\u2019s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.
Ranking 11th globally in antibiotic use, Vietnam faces a serious risk of drug resistance, and could be \u2018running out of treatment options due to antibiotic resistance\u2019.
Co-led by PSI Director Professor Sir Peter Horby, the RECOVERY trial was defined \"one of the most well-known studies supported by the NIHR with clear national and global impact.\u201d
Thanks to cutting edge research at NDM's Jenner Institute and Oxford University Clinical Research Unit (OUCRU), Oxford remains at the forefront of research to develop new vaccines to protect against this devastating disease.
![\"Person](\"https://www.ndm.ox.ac.uk/news/new-guidelines-published-for-monitoring-ibd-patients-to-prevent-bowel-cancer/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n